Vertex Pharmaceuticals Incorporated (LON:0QZU)
454.69
-5.81 (-1.26%)
Dec 5, 2025, 5:08 PM BST
Vertex Pharmaceuticals Revenue
Vertex Pharmaceuticals had revenue of $3.08B USD in the quarter ending September 30, 2025, with 10.99% growth. This brings the company's revenue in the last twelve months to $11.72B, up 10.33% year-over-year. In the year 2024, Vertex Pharmaceuticals had annual revenue of $11.02B with 11.66% growth.
Revenue (ttm)
$11.72B
Revenue Growth
+10.33%
P/S Ratio
9.95
Revenue / Employee
$1.92M
Employees
6,100
Market Cap
86.74B GBP
Revenue Chart
* This company reports financials in USD.
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 11.02B | 1.15B | 11.66% |
| Dec 31, 2023 | 9.87B | 938.50M | 10.51% |
| Dec 31, 2022 | 8.93B | 1.36B | 17.91% |
| Dec 31, 2021 | 7.57B | 1.37B | 22.06% |
| Dec 31, 2020 | 6.21B | 2.04B | 49.08% |
| Dec 31, 2019 | Pro | Pro | Pro |
| Dec 31, 2018 | Pro | Pro | Pro |
| Dec 31, 2017 | Pro | Pro | Pro |
| Dec 31, 2016 | Pro | Pro | Pro |
| Dec 31, 2015 | Pro | Pro | Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| AstraZeneca | 43.24B |
| GSK plc | 32.17B |
| Haleon | 11.02B |
| Smith & Nephew | 4.33B |
| Convatec Group | 1.72B |
| Hikma Pharmaceuticals | 2.35B |
| HUTCHMED (China) | 439.54M |
| Genus | 672.80M |
Vertex Pharmaceuticals News
- 1 day ago - Vertex Pharmaceuticals Inc at Citi Global Healthcare Conference Transcript - GuruFocus
- 1 day ago - 1 Reason I'll Never Sell Vertex Pharmaceuticals Stock - The Motley Fool
- 2 days ago - Check Out What Whales Are Doing With VRTX - Benzinga
- 2 days ago - Vertex Pharmaceuticals (VRTX) Upgraded by Morgan Stanley with Optimistic Outlook - GuruFocus
- 2 days ago - Vertex Pharmaceuticals Incorporated (VRTX) Presents at Citi Annual Global Healthcare Conference 2025 Transcript - Seeking Alpha
- 3 days ago - Why Is Vertex (VRTX) Up 2.7% Since Last Earnings Report? - Nasdaq
- 3 days ago - Vertex Pharmaceuticals (VRTX) Receives Rating Upgrade from Morgan Stanley | VRTX Stock News - GuruFocus
- 3 days ago - Vertex Up 9.2% in 3 Months: Should You Buy, Sell or Hold the Stock? - Nasdaq